CereVasc Inc., a company focused on improving the treatment of patients with hydrocephalus, announced the addition of DJ Cass as senior vice president of Business Development & Strategy and Janelle Arrambide as director of Clinical Operations, who will both support the development of the eShunt System expected to enter clinical trials by the end of this year.
 
Cass joins CereVasc from his role as group vice president, International for Insulet Corporation, where he led international commercial operations and partnerships. Prior to that role, he held business and strategic planning roles with Hologic (Cytyc). Arrambide brings more than 20 years of successful clinical trials experience including in the areas of neurosurgery and drug delivery to CereVasc having previously led clinical operations for EndoStim Inc. and Flowonix Medical.
 
“We have made great progress in the development of our technology and believe we have the potential to transform the treatment of patients who deal with the shortcomings of the current, 60-year-old open surgical approach to treat hydrocephalus. These additions to our leadership team are an important step in advancing our mission and achieving that goal,” said Dan Levangie, president and CEO of CereVasc. “We are excited to have DJ and Janelle join our team. I have worked along-side DJ for more than 20 years at Cytyc Corporation and most recently at Insulet Corporation. His drive, attention to detail, and versatility are a perfect match for our stage of development as we move the eShunt System into the clinic. Janelle brings very relevant Class III medical device experience to CereVasc, Inc. in the fields of neurosurgery and drug delivery. Her track record of accomplishing clinical milestones is very impressive, and she is a great fit for CereVasc at this critical stage in our evolution.”